Drug intelligence / Profile preview

PRAX-050

Development stage: Preclinical
Lead developer: Praxis Precision Medicines
Modality: Small Molecules

Overview

PRAX-050 is an early-stage small molecule drug candidate being developed by Praxis Precision Medicines. It is intended for the treatment of movement disorders. While the company's portfolio frequently focuses on modulating ion channels and neurotransmitter receptors to treat central nervous system disorders, the specific biological target and mechanism of action for PRAX-050 have not yet been publicly disclosed. The program is currently in the early stages of development, following the company's more advanced candidates like ulixacaltamide.

Beyond the preview

Go deeper on PRAX-050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRAX-050.

Explore the full profile